$2.5 Billion is the total value of BVF INC/IL's 81 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 18.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KYMR | Buy | KYMERA THERAPEUTICS INC | $151,787,000 | -24.8% | 3,586,658 | +12.8% | 6.07% | -17.2% |
| RLAY | Buy | RELAY THERAPEUTICS INC | $135,601,000 | +41.0% | 4,530,605 | +44.7% | 5.42% | +55.4% |
| RCUS | Buy | ARCUS BIOSCIENCES INC | $125,008,000 | -9.1% | 3,960,948 | +16.6% | 5.00% | +0.2% |
| ARGX | Buy | ARGENX SEsponsored adr | $99,702,000 | +31.7% | 316,204 | +46.3% | 3.99% | +45.1% |
| PTGX | Buy | PROTAGONIST THERAPEUTICS INC | $99,059,000 | -20.7% | 4,183,219 | +14.6% | 3.96% | -12.6% |
| RPTX | Buy | REPARE THERAPEUTICS INC | $83,429,000 | -18.6% | 5,858,776 | +20.6% | 3.34% | -10.3% |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $68,556,000 | +178.0% | 3,976,543 | +134.5% | 2.74% | +206.4% |
| KURA | Buy | KURA ONCOLOGY INC | $51,517,000 | +78.3% | 3,203,783 | +55.2% | 2.06% | +96.5% |
| Buy | EQRX INC | $49,666,000 | -7.3% | 12,025,570 | +53.0% | 1.99% | +2.1% | |
| ITOS | New | ITEOS THERAPEUTICS INC | $45,058,000 | – | 1,400,201 | +100.0% | 1.80% | – |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $41,620,000 | -9.4% | 2,394,714 | +14.0% | 1.66% | -0.2% |
| FDMT | Buy | 4D MOLECULAR THERAPEUTICS IN | $40,288,000 | -8.5% | 2,664,521 | +32.8% | 1.61% | +0.9% |
| New | CINCOR PHARMA INC | $30,437,000 | – | 1,735,293 | +100.0% | 1.22% | – | |
| ACIU | Buy | AC IMMUNE SA | $29,714,000 | -15.0% | 7,428,379 | +5.2% | 1.19% | -6.3% |
| STRO | Buy | SUTRO BIOPHARMA INC | $28,342,000 | +105.9% | 3,447,946 | +272.7% | 1.13% | +126.8% |
| VSTM | Buy | VERASTEM INC | $28,164,000 | -19.5% | 19,974,658 | +17.1% | 1.13% | -11.3% |
| PNT | Buy | POINT BIOPHARMA GLOBAL INC | $26,842,000 | +64.1% | 3,367,826 | +15.3% | 1.07% | +80.8% |
| Buy | TYRA BIOSCIENCES INC | $26,454,000 | +0.4% | 2,472,327 | +32.0% | 1.06% | +10.6% | |
| New | AN2 THERAPEUTICS INC | $24,363,000 | – | 1,616,665 | +100.0% | 0.98% | – | |
| EPIX | Buy | ESSA PHARMA INC | $22,839,000 | -43.6% | 3,695,629 | +29.6% | 0.91% | -37.8% |
| OVID | Buy | OVID THERAPEUTICS INC | $21,512,000 | +1.1% | 6,851,051 | +3.3% | 0.86% | +11.4% |
| GBIO | Buy | GENERATION BIO CO | $20,574,000 | +1437.7% | 2,802,950 | +1382.7% | 0.82% | +1579.6% |
| IDYA | New | IDEAYA BIOSCIENCES INC | $17,910,000 | – | 1,600,559 | +100.0% | 0.72% | – |
| RAIN | Buy | RAIN THERAPEUTICS INC | $17,881,000 | -53.1% | 3,526,729 | +19.2% | 0.72% | -48.3% |
| VIRX | Buy | VIRACTA THERAPEUTICS INC | $17,206,000 | +37.1% | 3,614,662 | +5.1% | 0.69% | +50.9% |
| JANX | Buy | JANUX THERAPEUTICS INC | $16,381,000 | -18.4% | 1,142,340 | +12.3% | 0.66% | -10.2% |
| CNTA | Buy | CENTESSA PHARMACEUTICALS PLCsponsored ads | $15,747,000 | +207.7% | 1,755,545 | +286.2% | 0.63% | +238.7% |
| IKNA | Buy | IKENA ONCOLOGY INC | $15,260,000 | -32.3% | 2,501,571 | +39.1% | 0.61% | -25.5% |
| MTEM | Buy | MOLECULAR TEMPLATES INC | $13,961,000 | +13.8% | 4,046,735 | +29.3% | 0.56% | +25.4% |
| Buy | PYXIS ONCOLOGY INC | $11,562,000 | -41.2% | 2,861,851 | +59.8% | 0.46% | -35.1% | |
| Buy | NUVALENT INC | $9,576,000 | +12.1% | 689,418 | +53.7% | 0.38% | +23.5% | |
| ELDN | Buy | ELEDON PHARMACEUTICALS INC | $9,167,000 | +50.8% | 2,326,710 | +68.8% | 0.37% | +66.1% |
| VYGR | Buy | VOYAGER THERAPEUTICS INC | $9,061,000 | +15001.7% | 1,189,100 | +5256.3% | 0.36% | +18000.0% |
| IVA | Buy | INVENTIVA SAads | $7,937,000 | +6.7% | 686,040 | +26.0% | 0.32% | +17.4% |
| ELEV | Buy | ELEVATION ONCOLOGY INC | $5,827,000 | -39.9% | 2,312,198 | +43.5% | 0.23% | -33.8% |
| CALA | Buy | CALITHERA BIOSCIENCES INC | $3,755,000 | -24.2% | 9,294,923 | +24.7% | 0.15% | -16.7% |
| RDUS | New | RADIUS HEALTH INC | $3,338,000 | – | 378,000 | +100.0% | 0.13% | – |
| JNCE | New | JOUNCE THERAPEUTICS INC | $861,000 | – | 126,797 | +100.0% | 0.03% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
| 3 | 2023-11-06 |
| 4 | 2023-11-06 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.